Stock Details
REGN is Regeneron Pharmaceuticals, Inc.'s stock. Stock exchange NasdaqGS (Currency USD). Average price in 50 days is 634.09$. Average daily volumn in 3 months 700.11k. Market cap 64.53B

Stock symbol : REGN. Exchange : NasdaqGS. Currency : USD
Lastest price : 587.47$. Total volume : 73.01k. Market state REGULAR
Click reload if you want to check the lastest price on market!!!

Regeneron Pharmaceuticals, Inc. (REGN)
Last Price

Previous Close591.13
Day Range586.17-596.21
Bid587.84 x 1k
Ask588.76 x 800
Average Volume700.11k
Market Cap64.53B
52 Week Range538.01-747.42
Trailing P/E8.43
Foward P/E13.56
Dividend (Yield %)N/A
Ex-Dividend DateN/A

Financial Details

According to Regeneron Pharmaceuticals, Inc.'s financial reports the company's revenue in 2021 were 16.07B an decrease( +100%) over the years 2020 revenue that were of 8.5B. In 2021 the company's total earnings were 8.08B while total earnings in 2020 were 3.51B( +166.67%).

Loading ...


Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vei... n occlusion. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma;Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

Market Cap:
Total Assets:
Total Cash:

News about "Regeneron Pharmaceuticals, Inc."

AE Wealth Management LLC Acquires 176 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Source from : Defense World - 11 hours ago

AE Wealth Management LLC grew its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Get Rating) by 1.8% during the first quarter, reports. The institutional ...See details»

Regeneron Completes Acquiring Sanofi's Stake In Libtayo

Source from : Business Insider - 10 hours ago

Regeneron Pharmaceuticals, Inc. (REGN) announced Friday that it has completed the acquisition of French drug major Sanofi's (SNYNF, ...See details»


Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Bought by Ritholtz Wealth Management

Source from : Defense World - 3 days ago

Ritholtz Wealth Management grew its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Get Rating) by 10.4% in the first quarter, Holdings reports. The fund owned 668 shares ...See details»

Regeneron (REGN) Eylea sBLA for Extended Regimen Accepted

Source from : Nasdaq - 1 days ago

Eylea is a VEGF inhibitor formulated as an injection for the eye. The sBLA is seeking label expansion of the drug for every 16-week 2 mg dosing regimen (after initial monthly doses) in patients with ...See details»


Gateway Investment Advisers LLC Sells 153 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Source from : ETF Daily News - 4 days ago

Gateway Investment Advisers LLC lessened its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Get Rating) by 13.9% in the first quarter, according to the company in its most recent ...See details»

Attention Biotech Investors: Mark Your Calendar For These July PDUFA Dates

Source from : Business Insider - 11 hours ago

The biotech sector is poised to end June on a positive note, despite largely disappointing regulatory decisions scheduled during the month, thanks to a reversal in broader market sentiment.See details»


Regeneron's EYLEA SBLA For 16-week Dosing Regimen In Diabetic Retinopathy Accepted For FDA Review

Source from : Nasdaq - 2 days ago

(REGN) said Wednesday that the U.S. Food and Drug Administration has accepted for review the EYLEA (aflibercept) Injection supplemental Biologics License Application or sBLA for an every 16-week 2 mg ...See details»

Regeneron: FDA to Review Extended Eylea Regimen in Diabetic Retinopathy >REGN

Source from : MarketWatch - 2 days ago

By Colin Kellaher Regeneron Pharmaceuticals Inc. on Wednesday said the U.S. Food and Drug Administration will review its application seeking approval of ...See details»

Regeneron Completes Acquisition of Checkmate Pharmaceuticals

Source from : Yahoo Finance - 1 month ago

2022 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it has successfully acquired Checkmate Pharmaceuticals, Inc., deepening its commitment to immuno-oncology ...See details»

Regeneron Pharmaceuticals, Inc.'s (REGN) Management Presents at Goldman Sachs 43rd Annual Global Healthcare Conference (Transcript)

Source from : Seeking Alpha - 17 days ago

Really pleased to have the Regeneron team with us ... we did end up buying Checkmate Pharmaceuticals about a month ago, which for the three years that we’ve been in existence, actually going ...See details»

Regeneron to gain exclusive rights to signature medicine from French collaborator

Source from : Times Union - 27 days ago

RENSSELAER – Regeneron Pharmaceuticals Inc. amended an agreement with Sanofi Biotechnology that will grant it exclusive worldwide development, commercialization and manufacturing rights to its ...See details»


When the Price of Regeneron Pharmaceuticals REGN Talks, People Listen

Source from : news.stocktradersdaily - 11 days ago

Short REGN under 621.55, target n/a, stop loss @ 623.35 Details The technical summary data is suggesting a short of REGN as it gets near 621.55, but the downside target is not available from the ...See details»

Regeneron to pay Sanofi up to $1.1 billion plus royalties for its stake in Libtayo collaboration

Source from : Morningstar%2c Inc. - 29 days ago

Regeneron Pharmaceuticals Inc. (REGN) announced Thursday an agreement in which it will pay up to $1.1 billion plus royalties for Sanofi S.A.'s (SAN.FR) stake in the Regeneron-Sanofi collaboration ...See details»

Regeneron Buys Checkmate, Shares Point Downward

Source from : Middle East North Africa Financial Network - 1 month ago

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) saw its shares lose strength to begin a holiday-shortened week, on the announcement it has successfully acquired Checkmate Pharmaceuticals ...See details»